Human medicines European public assessment report (EPAR): Tuznue, trastuzumab, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Cibinqo, abrocitinib, Date of authorisation: 09/12/2021, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Exforge HCT, amlodipine besilate,valsartan,hydrochlorothiazide, Date of authorisation: 15/10/2009, Revision: 28, Status: Authorised
Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 12, Status: Authorised
Human medicines European public assessment report (EPAR): Dafiro HCT, amlodipine besilate,valsartan,hydrochlorothiazide, Date of authorisation: 03/11/2009, Revision: 30, Status: Authorised
Human medicines European public assessment report (EPAR): Copalia HCT, amlodipine,valsartan,hydrochlorothiazide, Date of authorisation: 03/11/2009, Revision: 28, Status: Authorised
Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices
Combination Products Operational Group: agendas and highlight reports
Annual fees payable to the European Medicines Agency
Agenda - Combination products operational group, In vitro diagnostics (IVD) stream, 9 February 2026